Bio-Path Holdings, Inc. (BPTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
BPTH Stock Price Chart Interactive Chart >
BPTH Price/Volume Stats
|Current price||$3.55||52-week high||$8.62|
|Prev. close||$3.27||52-week low||$2.68|
|Day high||$3.55||Avg. volume||57,129|
|50-day MA||$3.31||Dividend yield||N/A|
|200-day MA||$4.20||Market Cap||25.42M|
Bio-Path Holdings, Inc. (BPTH) Company Bio
Bio-Path Holdings, Inc. focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. The company was founded in 2007 and is based in Bellaire, Texas.
Most Popular Stories View All
BPTH Latest News Stream
|Loading, please wait...|
BPTH Latest Social Stream
View Full BPTH Social Stream
Latest BPTH News From Around the Web
Below are the latest news stories about Bio-Path Holdings Inc that investors may wish to consider to help them evaluate BPTH as an investment opportunity.
HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2022 Virtual Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET. An audio webcast of the pr
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML PatientsHOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces a poster highlighting the safety and preliminary efficacy data of its Phase 2 study of prexigebersen (BP1001) was presented at the 2021 American So
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTH) to post earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Bio-Paths earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.35). Bio-Path posted earnings of ($0.57) per share during the same quarter last year, 
No summary available.
BPTH Price Returns